SCI Pharmtech Corp. (4119) AI Stock Analysis

SCI Pharmtech Corp.

(TWSE:4119)

Select Model

Rating:48Neutral

Price Target:TWD 49.00▲(1.03% Upside)

Action:initiatedcoverage

Date:11/09/26

Moderate financial performance driven by balance sheet strength is the primary factor, offset by weak technical momentum and stretched valuation.

Positive Factors

Conservative leverageConservative leverage gives SCI Pharmtech financial flexibility while earnings are recovering from recent weakness. Limited debt escalation reduces balance-sheet pressure and leaves the company better positioned to fund operations, manage volatility, and pursue pharmaceutical development without relying heavily on additional borrowing.

Negative Factors

Revenue contractionThe sharp 2025 revenue contraction signals weaker demand, product performance, or commercial execution than in the preceding growth period. If growth does not recover, lower scale can reduce operating leverage, constrain reinvestment, and make future earnings more dependent on a narrow set of products or markets.

SCI Pharmtech Corp. (4119) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 5.69B
Dividend Yield: 1.55%
Average Volume (3M): 169.26K
Price to Earnings (P/E): 95.7
Beta (1Y): 0.30
Revenue Growth: -18.83%
EPS Growth: -87.54%
Country: TW
Employees: 202
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

SCI Pharmtech Corp. Business Overview & Revenue Model

Company Description

SCI Pharmtech, Inc., founded in 1987 and based in Taoyuan City, Taiwan, specializes in the comprehensive lifecycle of pharmaceutical components. The company's core operations involve the research and development, manufacturing, and global distributio...

SCI Pharmtech Corp. Financial Statement Overview

Summary

Revenue recovery after 2021 setback but ongoing margin compression and profit volatility; strong balance sheet with low leverage offset by persistent negative free cash flow.

Income Statement

52Neutral

Balance Sheet

78Positive

Cash Flow

40Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.26B	1.34B	1.52B	1.20B	899.74M	864.22M
Gross Profit	281.04M	319.47M	410.67M	350.32M	291.18M	208.09M
EBITDA	360.24M	408.21M	909.92M	515.77M	492.07M	142.81M
Net Income	60.12M	107.37M	534.68M	294.72M	308.78M	55.70M
Balance Sheet
Total Assets	6.93B	6.89B	7.20B	6.69B	4.96B	4.19B
Cash, Cash Equivalents and Short-Term Investments	84.07M	74.80M	692.76M	1.03B	264.37M	692.63M
Total Debt	1.06B	987.18M	990.39M	1.04B	545.38M	2.15M
Total Liabilities	1.62B	1.49B	1.72B	1.59B	1.33B	869.26M
Stockholders Equity	5.31B	5.39B	5.48B	5.10B	3.63B	3.32B
Cash Flow
Free Cash Flow	-174.44M	-389.68M	-86.12M	-813.59M	-871.02M	-494.70M
Operating Cash Flow	223.88M	220.32M	860.52M	215.77M	296.56M	280.28M
Investing Cash Flow	-380.21M	-512.92M	-1.01B	-866.20M	-1.01B	-539.56M
Financing Cash Flow	-11.53M	-229.15M	-210.84M	1.43B	547.12M	-41.52M

SCI Pharmtech Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4119 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4166	70Outperform	TWD 5.47B	22.78	―	―	―	―
TW:1734	64Neutral	TWD 6.07B	17.33	―	3.13%	2.44%	-3.96%
TW:4746	64Neutral	TWD 5.43B	11.42	―	6.61%	-2.71%	―
TW:4167	60Neutral	TWD 6.30B	7.86	―	4.18%	-0.05%	64.82%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4119	48Neutral	TWD 5.85B	95.69	―	1.55%	-18.83%	-87.54%

* General Sector Average

Performance Comparison

TW:4119 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4119	SCI Pharmtech Corp.	48.50	-0.61	-1.25%
TW:1734	Sinphar Pharmaceutical Co. Ltd.	30.15	1.76	6.19%
TW:4166	Orient Pharma Co., Ltd.	22.55	-2.05	-8.33%
TW:4167	Savior Lifetec Corp.	19.25	2.48	14.77%
TW:4746	Formosa Laboratories, Inc.	45.40	-15.89	-25.92%
TW:7754	Annji Pharmaceutical Co., Ltd.	69.40	24.75	55.45%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

SCI Pharmtech Corp. AI Stock Analysis